Detailing the biotech life cycle

Detailing the biotech life cycle. The inflection points of the drug development process Phase Discovery Preclinical Phase1 Phase 1b/2a Phase 2b Phase 3 FDA Review Marketed Drug Typical Cost ($mm) $5 $5-10 $5-10 $10-15 $15-25 $40-100 $5 $100s Sources of Capital Seed Venture Venture Seed Venture Seed Venture Growth Venture Growth Public Venture Growth Venture Public Growth Public The capital required for each

Written bySam Hall and Alastair J.J. Wood

| 2 min read

Save for Later

Listen with Speechify

0:00

2:00

The capital required for each stage of development varies, escalating significantly as a drug enters large clinical trials in the later stages of development. As a result of this growing demand for capital, different investor populations are generally involved in funding the very early versus very late stages of development.

The percentage of the company owned by founders declines significantly over time, despite significant increases in value with each successive round of financing. This effect is typically offset by the granting of stock options to founders and management in order to maintain their ownership positions at desired levels. (Series valuations based on Recombinant Capital estimates.¹)

1. McCully, Michael G. Digging into the Data: The Latest Trends in Alliance Structures and Valuations. Drug Delivery Partnerships 2008. January 23, 2008.

Financial Growing Pains of a Biotech

Common Pitfalls

Picking the right exit

Editorial: Biotech: Solid to Spectacular?

Slideshow: The inflection point

Success ...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!

Join for free today

Already a member? Login Here